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Objectives: The role of random, four-quadrant biopsy (i.e. systematic biopsy) in Barrett’s 
oesophagus surveillance has been questioned given its drawbacks and the emergence of high-
resolution endoscopy and advanced imaging modalities. Our study aims to assess whether 
neoplastic pathology is typically diagnosed in routine clinical practice by random, four-quadrant 
or targeted biopsy whilst using high-resolution endoscopy.  
 
Methods: The Nottingham University Hospital Barrett’s oesophagus dysplasia database was 
retrospectively analysed. Endoscopic and histopathologic data pertaining to the initial endoscopy 
in which pathology was diagnosed was extracted from the medical records. The most advanced 
histopathologic abnormality at initial diagnosis and within twelve months were noted. The 
corresponding endoscopic impression at initial diagnosis was used to group cases per type of 
biopsy – random, four-quadrant or targeted. Pearson’s chi-squared test of independence was used 
to analyse the relationship between the type of biopsy and diagnosis, indication for endoscopy, 
endoscopist level and advanced techniques used.  
 
Results: Of the 222 patients involved in the study - a higher proportion were diagnosed through 
random, four-quadrant biopsy (72.97%) than targeted biopsy (27.03%). 90.91% of low-grade 
dysplasia, 71.43% of high-grade dysplasia and 50% of intramucosal adenocarcinoma cases were 
diagnosed by random, four-quadrant biopsy. Across all grades of clinicians, patients were 
typically diagnosed through random, four-quadrant biopsy. However, amongst specialist 
consultant endoscopists (n=10) the proportion was equal.  
 
Conclusions: Our findings strongly emphasize the importance of random, four-quadrant biopsy 
in the detection of not only low-grade dysplasia, but also high-grade dysplasia and early invasive 
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Over the past forty years, the incidence of oesophageal adenocarcinoma has increased 
dramatically in the Western world (1). Coupled with its grim prognosis, a five-year overall 
survival rate of 15%, the epidemic of oesophageal adenocarcinoma is of significant concern (2). 
The major risk factor in the development of oesophageal adenocarcinoma is Barrett’s 
oesophagus (BO) – a premalignant lesion characterized by the replacement of the normal 
squamous epithelium of the distal oesophagus with metaplastic columnar epithelium (3). 
Barrett’s oesophagus is associated with an annual risk of 0.33% for adenocarcinoma 
development (4), which increases in proportion to length of the Barrett’s segment (5–6). This 
occurs through a sequence of low- and high-grade dysplasia (7). In the presence of dysplasia the 
annual risk of cancer increases dramatically (8), thus necessitating treatment or intensified 
surveillance (11).     
 
Barrett’s surveillance is intended to detect oesophageal neoplasia at a pre-invasive stage, or if 
cancer does develop to diagnose it at an earlier stage, when it may be more amenable to 
intervention (9). The current standard of care in Barrett’s surveillance is the Seattle protocol – 
targeted biopsies of visible lesions followed by random, four-quadrant biopsies at 1-2 cm 
intervals throughout the Barrett’s segment (10–14). However, the Seattle protocol has significant 
limitations including sampling error, as well as its costly, labour- and time-intensive nature. This 
has resulted in widespread non-adherence by endoscopists that has been associated with reduced 
dysplasia detection (15–17).   
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The emergence of high-resolution white-light video endoscopy and advanced imaging modalities 
has raised the question of whether random, four-quadrant biopsies are still required in Barrett’s 
surveillance, as it is believed that such modalities have the potential to improve the detection and 
characterization of mucosal lesions at an early stage. This is analogous to the situation in 
inflammatory bowel disease where random biopsies for dysplasia detection have largely been 
replaced by dye spray endoscopy (18). The diagnostic accuracy of high-resolution versus 
standard resolution white-light endoscopy has not been evaluated in a randomized controlled trial 
in Barrett’s oesophagus, but a retrospective cohort study found that the former was associated 
with increased targeted dysplasia detection (19). The evaluation of advanced imaging modalities 
has largely been confined to clinical trials and surveillance programs involving selected patient 
populations in the context of academic medical centres, in which they have shown potential for 
identifying early neoplasia (12,20–23).  
 
Our study aims therefore to assess whether the initial diagnosis of neoplastic pathology in the 
context of Barrett’s oesophagus is typically made by targeted or random, four-quadrant biopsy in 













Study design  
 
This is a retrospective cohort study involving two-hundred and twenty-two patients selected from 
the Nottingham University Hospital Barrett’s Dysplasia Database.  
 
Of the 378 patients in our Barrett’s Dysplasia Database, approximately forty percent (n=156) 
were excluded. We excluded patients who never received a diagnosis greater than ID, those 
diagnosed prior to 2008 (to ensure that our analyses reflect the use of modern endoscopic 
modalities), and those for whom the relevant endoscopy or histopathology reports were not 
available. The remaining patients who were included in this study (n=222) had been diagnosed 
with Barrett’s oesophagus with dysplasia between 2008 to 2016. The majority (n=152) were 
initially assessed at the tertiary referral centre, however, 70 were initially assessed at one of four 
district general hospitals, before referral to the tertiary referral centre for expert evaluation, 
typically for newly-diagnosed HGD or IMCA.  
 
The study was performed under approval from Nottingham Health Science Biobank ACP 00035, 
and received a waiver of informed consent. Permission to access medical records was granted by 
the appropriate senior clinician and/or administrator affiliated with each hospital involved in this 
study.  
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Data collection  
 
We retrieved and analysed the medical records for each patient initially evaluated at the tertiary 
referral centre or district general hospitals. We defined as the ‘index endoscopy’ the first 
occurrence of LGD, HGD or IMCA for each patient except in the small number of cases (n=17), 
where there was a history of ID or above which had previously remitted for a variable time 
period without treatment. In these few cases, the index endoscopy was that which first detected 
the currently observed period of dysplasia. The findings were independently verified by two 
expert gastrointestinal histopathologists in each case. The following relevant data was extracted 
from the medical and pathological records for each index endoscopy:  
 




Length of Barrett’s segment.  
 
The endoscopic equipment and advanced imaging modalities used:  
▪ All index endoscopies were high-resolution, white-light video endoscopies. Of 
these, some were aided by advanced imaging modalities (n=16), such as acetic acid, 
auto-fluorescence imaging and narrow-band imaging.   
▪ All endoscopies were performed using the Olympus endoscopy system.  
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 Prevalent versus Incident cases   
▪ Dysplasia was considered to be prevalent where an initial diagnosis of Barrett’s 
dysplasia was made at the time of Barrett’s diagnosis being prompted by patient 
symptoms.  
▪ Dysplasia was considered to be incident when diagnosed during ongoing 
surveillance of Barrett’s oesophagus .  
▪ Prior diagnosis of ID or above refers to incident cases in whom there is a prior 
history of indefinite for dysplasia or above.  
 
The type of biopsy used – random, four-quadrant or targeted – was ascertained using the 
endoscopists record or request form corresponding to the biopsy exhibiting the most 
advanced histological abnormality at index endoscopy. The endoscopist impression was 
codified into one of the following seven groups, which accommodate a variety of 
descriptive terms that were noted in endoscopy reports. Groups 1-3 were categorized as 
random, four-quadrant biopsy (although being a retrospective study, this group also 
includes all randomly taken non-targeted biopsies). Groups 4-7 were categorized as 
targeted biopsy.  
1. “Barrett’s oesophagus”  
2. “Inflammation”  
3. “Barrett’s oesophagus with inflammation”  
4. “Slight irregularity”  
5. “Suspicious”  
6. “Cancer”  
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7. “Ulcer”   
 
The most advanced histological diagnosis noted at index endoscopy (i.e. ID, LGD, HGD 
or IMCA).  
 
The most advanced histological diagnosis noted within in twelve months after index 
endoscopy (i.e. LGD, HGD or IMCA). The rationale for acquiring this data was to ensure 
that the true histological diagnosis at index endoscopy was ascertained, and not 
underestimated as a result of sampling error.  
 
The endoscopist grade:  
▪ Barrett’s specialist endoscopist – a consultant gastroenterologist who specializes 
in Barrett’s oesophagus  
▪ Consultant – any other type of consultant or associate specialist  
▪ Fellow   
▪ Registrar   
▪ Nurse practitioner 
 
Data analysis  
 
We calculated proportions of each category of dysplasia detected by random, four-quadrant and 
targeted biopsies. We then similarly calculated the proportions of cases detected by random, 
four-quadrant and targeted biopsies among cases where dysplasia was incident, prevalent or 
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recurrent and stratified this result by the level of dysplasia (HGD, LGD, IMCA). Proportions of 
dysplasia diagnosed by random, four-quadrant and targeted biopsies were similarly calculated for 
differing levels of expertise of the examining endoscopist. 
 
We went on to examine the proportions of each level of dysplasia detected by standard white 
light endoscopy – Olympus Lucera video endoscopy system with GIF Q260 and H260 
gastroscopes – and by more advanced modalities, and the proportions associated with differing 
clinical endoscopic impressions at the index endoscopy. 
 
For all of these comparisons the hypothesis of difference between categories was tested using a 



















Of the 222 patients identified, more than 80% were male with a mean age of 67.43 years, and 
mean length of Barrett’s segment of 5.39 cm.   
 
Our principal finding was that over seventy percent of all cases were diagnosed through random, 
four-quadrant biopsy, almost three times as many as targeted biopsy (Table 1).  Only 9.09% of 
low-grade dysplasia was diagnosed through targeted biopsy; but more surprisingly, only 28.57% 
of high-grade dysplasia and 50% of intra-mucosal adenocarcinomas were detected through 
targeted biopsy. This means that half of early Barrett’s neoplasia was diagnosed by random, 
four-quadrant biopsy. High-grade dysplasia was over three times as likely to be diagnosed by 
targeted biopsy as low-grade dysplasia, and intra-mucosal adenocarcinoma was almost twice as 
likely to be diagnosed through targeted biopsy as high-grade dysplasia.  
 
Greater than a third of prevalent cases were diagnosed through targeted biopsy, almost three 
times as many as incident cases, and approximately sixty percent of cases in which a prior 
diagnosis of indefinite for dysplasia or above was made were diagnosed through targeted biopsy 
(Table 2).   
 
Barrett’s specialist endoscopists diagnosed fifty percent of cases through targeted biopsy - almost 
twice the proportion so diagnosed by the other endoscopist grades combined (Table 3), but the 
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absolute number of cases was small (n=10), and the differences between groups of endoscopists 
did not reach statistical significance.   
 
The vast majority of targeted biopsies were performed using white-light endoscopy – with only 
sixteen cases diagnosed using advanced imaging modalities.     
 
There were eight cases in which “inflammation” alone was listed as the endoscopist impression. 
However, histological analysis found that LGD was noted in four of these cases. Notably, the 
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χ 2 = 23.35, degrees of freedom = 2, p < 0.001  
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Advances in endoscopy have held out the tantalising prospect of replacing random, four-
quadrant biopsies as per the Seattle protocol as standard of care in Barrett’s surveillance. Whilst 
it is generally agreed that random, four-quadrant biopsy as part of the Seattle protocol is 
important (10–14), the emergence of high-resolution white-light endoscopy and advanced 
imaging modalities has raised the question as to whether it may be possible to use targeted 
biopsies in lieu of random, four-quadrant biopsies without compromising neoplasia detection 
(22). This has the obvious advantage of reducing endoscopy and pathology workload, but is only 
viable if detection of dysplasia is not compromised. A switch from random to targeted biopsies 
has to some extent been successfully adopted in surveillance of inflammatory bowel disease 
(IBD) (18,24), with dye-spray endoscopy replacing random biopsies in some centres. However, 
there are substantial differences in this respect between BO and IBD. Firstly, the overall length 
of BO mucosa is much smaller than that required to be surveilled in IBD. This means that it 
would be impossible in IBD to achieve the same coverage with random biopsies as per the four-
quadrant biopsy per two centimetres in Barrett’s oesophagus. There is also good evidence that 
random sampling of the large bowel mucosa is relatively ineffective in detecting dysplasia in 
IBD.   
 
This study has clearly demonstrated that in routine endoscopy practise within our region, 
encompassing several district general hospitals and one tertiary referral centre, which should be 
generalisable to the entire NHS – random, four-quadrant biopsy is much more effective in 
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detecting dysplasia than targeted biopsy alone. Over seventy percent of all cases were detected 
through random, four-quadrant biopsy – an observation that strongly emphasizes the role of 
random, four-quadrant biopsy in Barrett’s surveillance. The consensus in the literature is that 
non-adherence with the Seattle protocol amongst endoscopists is widespread, and is associated 
with a reduction in dysplasia detection (15–17). In light of our results, this is a significant 
concern.   
 
We also made several other observations. Firstly, prevalent cases - those whose dysplasia was 
detected at the initial diagnosis of Barrett’s - were three times more likely to be diagnosed 
through targeted biopsy than incident cases - those with known Barrett’s who had dysplasia 
detected arising under surveillance. It is reasonable to suggest that prevalent cases – that is, 
patients whose gastroscopy is likely to have been prompted by clinical symptoms – are more 
likely to have an underlying macroscopic lesion, which may then be sampled by targeted biopsy, 
as opposed to patients undergoing routine surveillance. Secondly, approximately sixty percent of 
cases with a prior diagnosis of indefinite for dysplasia or above were diagnosed through targeted 
biopsy. It is possible that those with prior indefinite for dysplasia or above have a greater 
likelihood of developing a visible neoplastic lesion, which is subsequently diagnosed through 
targeted biopsy. On the other hand, it is also possible that knowledge of prior pathology may lead 
endoscopists to conduct a more careful inspection, through which more lesions are detected by 
targeted biopsy. Thirdly, we found an association between the severity of pathology and 
likelihood of diagnosis through targeted biopsy, in that, more advanced pathology was typically 
diagnosed by targeted biopsy. This is in keeping with the general belief that low-grade dysplasia 
is often invisible endoscopically. Surprisingly, however, most high-grade lesions were also 
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detected by random, four-quadrant biopsy and of particular interest, only fifty percent of intra-
mucosal adenocarcinoma was diagnosed by targeted biopsy. This included 4 cases where intra-
mucosal adenocarcinomas were detected by biopsies taken for suspected oesophagitis without a 
clinical diagnosis of Barrett’s oesophagus. This has implications not only for biopsy schedules in 
Barrett’s oesophagus, but also in oesophagitis.  
 
Barrett’s specialist advanced endoscopists diagnosed fifty percent of cases through targeted 
biopsy - almost twice the proportion so diagnosed by the other endoscopist grades combined. It 
is likely that advanced training and experience played a role in the greater diagnostic yield of 
Barrett’s specialist endoscopists. However, the number of cases was small, and it is questionable 
whether it is feasible for the majority of endoscopists diagnosing and surveilling BO to develop 
the concentrated experience necessary to recognise more subtle abnormalities. Similarly, other 
studies have also found that specialist endoscopist cohorts were associated with greater dysplasia 
detection (25–26). It has been suggested that – in the hands of an expert endoscopist – the ability 
to dispense with random, four-quadrant biopsies may become a reality in the near future. 
However, our findings challenge this perspective, suggesting that even Barrett’s specialist 
endoscopists only diagnosed fifty percent of cases through targeted biopsy.  
 
The vast majority of cases diagnosed by targeted biopsy were made using high-resolution white-
light endoscopy rather than advanced imaging modalities. In fact, only sixteen cases were 
diagnosed using advanced imaging modalities, approximately one-third of that of white-light 
endoscopy. It is therefore reasonable to suggest that advanced imaging modalities play only a 
minor role in Barrett’s surveillance at present – a conclusion that reflects current medical society 
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guidelines, which have not recommended advanced imaging modalities for routine use (10–
14,22), as well as the realities of current endoscopy practice in the UK.   
 
The main strength of this study is its generalizability. It includes patients evaluated in both 
tertiary referral and district general hospitals, as well as a range of endoscopist grades. However, 
we readily accept that there are also certain limitations. Firstly, the retrospective, observational 
study design could increase risk of bias. However, by including virtually every case of dysplasia 
this should be ameliorated. Secondly, the small sample size reduces confidence in certain results, 
such as those involving Barrett’s specialist endoscopists and advanced imaging modalities. 
However, we believe that this does not affect the strength of our main conclusions. Thirdly, we 
do not know the extent to which all endoscopists applied the Seattle protocol fully, but from 
previous audits elsewhere we know that that fewer biopsies than recommended are often taken. 
This is however a conservative bias relative to our main conclusion, in that if the Seattle protocol 
had been followed it is likely that random, four-quadrant biopsy would have picked up even a 
greater number of dysplastic cases (17,27).    
 
In conclusion, we found that half of intra-mucosal adenocarcinomas and over seventy percent of 
all cases in our study were detected through random, four-quadrant biopsy. These findings 
strongly emphasize the importance of random, four-quadrant biopsy in the detection of not only 
low-grade dysplasia, but also high-grade dysplasia and intra-mucosal adenocarcinoma as part of 
Barrett’s surveillance. It is therefore clear that the Seattle protocol remains the gold-standard in 
the era of high-resolution video endoscopy and advanced imaging modalities. This study 
highlights several future directions. Firstly, it is important to tackle the problem of endoscopist 
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non-adherence with regards to the Seattle protocol. Secondly, it is important to place emphasis 
on clinical training in order to improve the diagnostic yield of targeted biopsy using modern 
high-resolution video endoscopy. Thirdly, any new imaging modality or technique requires 
further assessment in unselected patient populations in order to determine clinical utility in 
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